Sign In
Buy VERX
$12.91
+0.310 (+2.46%)
At Close: Jul 31, 2026
New Vertex Research Signals a Turning Point for Indirect Tax and Compliance: The Rise of Decision-to-Defense
10:05am, Thursday, 30'th Jul 2026
Drawing on more than 2,100 enterprise leaders across two independent research firms, the findings reveal two compounding forces — Defensibility Drift and CompOps Drag — that widen a Compliance Con
AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions
07:00am, Wednesday, 29'th Jul 2026
VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions.
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect?
12:36pm, Monday, 27'th Jul 2026
VRTX heads into its Q2 earnings release with Trikafta, Alyftrek, Casgevy and Journavx in focus as investors watch product sales and updates on ongoing pipeline studies.
Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching
07:45pm, Sunday, 19'th Jul 2026
Vertex Pharmaceuticals' latest acquisition grants it access to products with $5 billion peak annual sales potential. The company's business is strong thanks to its dominance in its core market and new
Vertex to Announce Second Quarter 2026 Financial Results on Monday, August 3, 2026
04:30pm, Tuesday, 14'th Jul 2026
KING OF PRUSSIA, Pa., July 14, 2026 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ:VERX), a leading provider of enterprise compliance technology for global commerce, today announced that it will release sec
Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals
08:00am, Tuesday, 14'th Jul 2026
Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.
Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?
02:27pm, Monday, 13'th Jul 2026
Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
05:03pm, Saturday, 11'th Jul 2026
Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strat
Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?
04:05am, Friday, 10'th Jul 2026
Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other tr
Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'
07:45am, Thursday, 09'th Jul 2026
On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, named Roundhill Memory ETF (NASDAQ:DRAM) as her final trade.
Vertex's Crinetics Deal Balances Growth with Integration Risk
09:05am, Wednesday, 08'th Jul 2026
Vertex Pharmaceuticals NASDAQ: VRTX recently announced its plans to acquire Crinetics Pharmaceuticals NASDAQ: CRNX for $10 billion. The deal, which has already been approved by the board of dir
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It.
03:28am, Wednesday, 08'th Jul 2026
Crinetics' Palsonify was FDA-approved late last year. The company's atumelnant is currently in late Phase 3 clinical testing.
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know.
11:00pm, Tuesday, 07'th Jul 2026
Vertex agreed to buy Crinetics for $85 per share in cash, about $10 billion in equity value. The deal adds a newly launched acromegaly drug and a late-stage candidate with more than $5 billion in comb
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
04:00pm, Tuesday, 07'th Jul 2026
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets close. The comp
Crinetics shares surge after Vertex agrees to $10B cash buyout
09:38am, Tuesday, 07'th Jul 2026
Crinetics Pharmaceuticals shares surged after Vertex Pharmaceuticals announced an agreement to acquire the endocrinology-focused biotech company in a deal valued at approximately $10 billion. The all-
